FDA Approves Tzield for Pediatric Patients with Stage 3 Type 1 Diabetes
The FDA granted accelerated approval for Tzield (teplizumab) to delay insulin production decline in pediatric patients with Stage 3 T1D.
Asset / Drug
Drug and asset intelligence for Endocrinology with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.